Limited data are available concerning long-term prostate cancer (PCa)-related medical costs for use in assessing PCa prevention strategies. The aim of this study was to examine treatment, long-term survival, and long-term PCa-related costs by cancer stage. Costs in phases of care based on the natural history of PCa were also examined. Our data illustrate that initial care is characteristic of a rapid rate of cost accrual. This rate then decreases during continuing care. For terminal care, only stage IV resumes a rate of cost accrual similar to initial care. With average PCa-related costs of $18 168 observed over an average follow-up of 4 years, prevention strategies may result in a reduction in medical costs.
Introduction
Prostate cancer (PCa) is one of the most commonly diagnosed cancers in the United States. 1 According to the American Cancer Society, there will be 192 280 newly diagnosed cases in 2009 and 27 360 men will die of the disease, making PCa the second leading cause of cancer death in American men. 1 Local and regional PCa account for more than 90% of all PCa cases and the 5-year relative survival rate for these stages approaches 100%. 1 Survival rates have increased dramatically over the past 25 years. 1 These increases are attributed to better treatment and advances in detection leading to earlier diagnosis. 1 Pharmacologic therapies are undergoing evaluation for the prevention of PCa. A phase III study examining finasteride has been completed and results have shown a 25% reduction in PCa over 7 years. 2 Another 5-alpha reductase inhibitor, dutasteride, is also currently being evaluated in a phase III trial. 3 As additional data become available regarding the benefits and risks of these agents, an examination of their economic impact will also be important. This requires an assessment of the additional treatment costs with future savings these strategies offer in terms of preventing or delaying PCa.
Although recent studies have examined PCa-related costs from a Medicare perspective using either the Surveillance, Epidemiology, and End Results (SEER)-Medicare data, [4] [5] [6] the Medicare 5% public use files, 7 or the CaPSURE database, 8 there are few recent studies examining costs in phases of care beyond initial treatment and stratified by cancer stage. Furthermore, many of the studies identified only examine costs for patients diagnosed with early stage PCa. [6] [7] [8] A few older studies 9, 10 have examined costs in phases of care beyond initial treatment and have stratified estimates by cancer stage. However, these studies consider costs over earlier periods (1990-1991 9 and 1973-1991 10 ), which may be less relevant today given the changes in approach to PCa diagnosis and treatment that have occurred. The purpose of this study was to examine treatment, long-term survival, and long-term costs by cancer stage using data from the SEER-Medicare linked database in patients diagnosed with PCa during 1991-2002.
Methods

Data source and patient population
We identified patients with PCa from a database linking cancer registry information with Medicare claims (SEERMedicare). The database and its contents have been described in detail elsewhere. 11 At the time analyses were conducted, data were available on incident cancer cases representing B26% of the US population with Medicare claims available from 1991 through 2004. 12 Male patients aged 65 years and older with a first primary diagnosis of PCa between 1 January 1991 and 31 December 2002 were selected from SEER. A sample of male patients from the random 5% sample of Medicare beneficiaries without cancer were selected and matched to cases on 5-year age groups to estimate background medical costs unrelated to PCa. Details related to the sample selection procedures for the PCa and non-cancer cohorts have been described in a prior study examining first-year PCa costs. 4 
Estimation of monthly treatment phase costs
We used a phased-based model similar to a previous study to estimate medical-care costs. 13 Using survival data from SEER, the period of time from diagnosis until death (or date of censoring) was divided into distinct phases of care (initial, continuing, and terminal care). The number of months each patient contributed to a particular phase was determined using an algorithm designed to model the natural history of PCa as described in Brown et al. 13 For patients surviving X18 months and dying before 2004, the initial phase was defined as the first 6 months after PCa diagnosis, the terminal phase as the last 12 months before death, and the continuing care phase as the time between initial and terminal phases. For patients surviving o18 months, the final 12 months of follow-up were allocated first to the terminal phase and the remaining months were defined as initial phase. The total average monthly cost of health-care utilization was calculated for each patient by summing the payment data on each Medicare claim for each treatment phase and then dividing by the total number of follow-up months patients contributed to each phase. The Medicare claims from 1991 to 2004 were used to estimate phase-specific costs. For patients alive as of December 2004, only cost data through 2003 were analyzed because we could not determine if costs were related to terminal or non-terminal care. During this period, the main initial therapeutic options including prostatectomy, radiation, and hormone therapy were available. All cost data were inflated to 2004 constant dollars using the medical-care services component of the Consumer Price Index.
The analysis of monthly PCa treatment phase costs was conducted on patients diagnosed with PCa over a 12-year period (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) . A sensitivity analysis was carried out to ascertain whether monthly costs for patients diagnosed during 1998-2002 were comparable to the primary analysis (years 1991-2002).
Estimation of average long-term costs
The incremental differences in average monthly treatment phase costs between PCa cases and the non-cancer cohort were assumed to be PCa-related costs. Phasespecific monthly cost estimates were combined with survival data from SEER to calculate long-term costs for patients from diagnosis until either death or end of follow-up in the Medicare claims. First, the SEER data were used to estimate the proportions of patients, stratified by stage, who survived for each of the different time periods after diagnosis. Next, we estimated PCa-related costs for each survival time by using the corresponding phase-specific monthly cost estimates and then summing these costs across the number of months patients contributed to each treatment phase. As patients survived different lengths of time, we weighted our cost estimates based on the percentage of patients surviving each time period. Long-term total population costs were estimated similarly to PCa-related costs. Modelbased estimates of total long-term costs were validated by comparing results with total average costs based on the actual Medicare payments appearing on the claims.
Statistical methods
Non-parametric bootstrap methods were used to calculate 95% confidence intervals (CIs) around cost estimates. 14 We re-sampled with replacement from the study dataset to create 1000 random samples. Total and PCa-related costs were calculated for each of the 1000 replicates. CIs were derived from the sample distribution of costs of the 1000 replicates at the 2.5 and 97.5% quantiles. Life expectancy was estimated by cancer stage using the Kaplan-Meier method. The time to death was calculated as the number of months from PCa diagnosis until death. Patients alive as of their last day of data in the Medicare claims were censored. Statistical significance was evaluated at a ¼ 0.05 using the log-rank test. Table 1 compares the baseline characteristics of PCa patients to the non-cancer cohort. Non-cancer patients Costs of prostate cancer ME Stokes et al were comparable to PCa cases with respect to age and survival. A larger proportion of PCa patients resided in the Midwest and West compared to non-cancer patients. Mean age at entry into each phase of care was similar between PCa cases and age-matched controls.
Results
Patient characteristics
Initial PCa patterns of treatment
The use of specific PCa-related medical care observed during the first 6 months of follow-up is shown in Table 2 . Almost one-third of all PCa patients did not receive an active therapy during initial treatment. Usage of prostatectomy was highest for stage III (column % 56.4, row % 47.3) and lowest for stage I (column % 6.4, row% 17.4). Treatment with external beam radiation and brachytherapy was more common among lower versus higher staged patients. There was very little use of cryotherapy (All stages column % 0.1) or bilateral orchidectomy (All stages column % 0.2).
Monthly treatment phase cost estimates
Monthly PCa-related and other costs, by treatment phase and cancer stage, are displayed in Figure 1 . PCa-related costs in each phase were estimated by subtracting the total monthly costs of patients without cancer from the total monthly costs of PCa patients. The non-cancer cohort was used to estimate background medical costs unrelated to PCa (other costs). These results are based on a subsample of the data excluding monthly costs in the 95-100 percentiles. Investigation of the data led to the conclusion that cost outliers were driving up mean monthly costs for each treatment phase and inflating long-term estimates; when patients with costs in the 95-100 percentiles were excluded from the estimation of mean monthly costs, model-based estimates of long-term costs yielded results that were more consistent with actual mean Medicare payments (Actual $47 153 versus Model $46 751). The greatest difference in monthly costs between PCa and non-cancer patients was in the initial phase with an incremental difference averaging $1857 (Figure 1 
Survival estimates
Kaplan-Meier survival curves after initial cancer diagnosis are shown in Figure 2 . The median survival time was B36 months among patients diagnosed at stage IV. Survival times were considerably longer for men diagnosed in stages I-III. Approximately 61, 56, and 55% of stages III, II, and I patients, respectively, were alive 120 months after the initial PCa diagnosis versus 18% of stage IV patients (Po0.001, all comparisons).
Average long-term costs
Long-term cost estimates for PCa patients are displayed in Figure 4 plots cumulative PCa-related costs (undiscounted) after cancer diagnosis using mean monthly Costs of prostate cancer ME Stokes et al PCa-related phase specific estimates and the average number of months patients contributed to each treatment phase. Costs after PCa accumulate rapidly for all stages in the first 6 months reflecting a period of relatively high medical resource use characteristic of treating cancer. After initial treatment, the rate of cost accrual slows and levels off for stages I-III throughout continuing and terminal care, respectfully. Stage IV patients had higher terminal costs versus non-cancer patients and also contributed more months of follow-up to the terminal phase compared with stages I-III. This is reflected in the plot as stage IV PCa costs resume a rate of cost accrual similar to initial care. Patients diagnosed at stage III had higher PCa-related costs compared with stages I and II. Stage III patients used PCa-related medical care to a greater extent during the initial treatment phase (Table 2) , and although monthly continuing care phase costs were lowest for stage III, this cohort contributed more continuing care months versus stages I and II because of longer survival times ( Figure 2 ). Men diagnosed at stage III were also younger versus stages I and II.
Sensitivity analysis
We observed similar relationships between initial, continuing, and terminal care monthly costs for the cohort of PCa patients diagnosed during [1998] [1999] [2000] [2001] [2002] Figure 1 Mean monthly costs among prostate cancer (PCa) patients, by stage and treatment phase. wRefers to the background medical costs unrelated to PCa. Other costs estimated using sample of Medicare beneficiaries without cancer. Costs of prostate cancer ME Stokes et al occurred during initial treatment with incremental costs ranging from $1615 to $2331 for stages I and III, respectively.
There are few studies in the literature that have estimated PCa-related costs, by cancer stage among patients diagnosed with local, regional, and distant PCa in which the staging information has come directly from a clinical source.
9,10 Both Taplin and Fireman have shown that remote cancer stages have lower initial costs relative to regionally staged patients. Fireman also concluded that stage effects on 15-year long-term cost estimates were modest and insignificant for PCa. 10 Our results agree with these studies in that our initial care costs for stage IV were lower versus stage III. However, results of our long-term analysis contrast with Fireman in that PCa-related costs for stage IV were nearly $7000 higher versus stage III. This difference may be the result of shifting patterns of care related to the sampling of patients in different time frames. Fireman sampled patients diagnosed with PCa during an earlier period (1973-1991), whereas our study included patients diagnosed from 1991 to 2002. A few studies in the literature were identified which estimate health-care costs during initial treatment in Costs of prostate cancer ME Stokes et al patients with early stage PCa using Medicare databases. 6, 7 Our initial care PCa-related cost estimates among stages I (Figure 4 , $9006 at month 6) and II ( Figure 4 , stage II $10 480 at month 6) are at the lower end of the ranges of estimates provided by Zeliadt 6 ($9182-15 137) and Brandeis 7 ($11 955-30 338). We attribute this difference primarily to the fact that both Zeliadt and Brandeis included only patients who were actively treated whereas the current analysis includes those receiving expectant management. Furthermore, the study by Brandeis used charges as a proxy for estimating costs rather than actual Medicare reimbursements.
This study has several limitations. The study population was limited to Medicare patients aged X 65 years. As older men are more likely to receive expectant management as initial therapy, our cost estimates are probably lower in comparison to younger cohorts. The Medicare claims are primarily used for administrative purposes in obtaining reimbursement for services provided to Medicare-eligible patients; research is not the intended purpose of these data. 15 The use of the Medicare claims to estimate medical costs is limited to the services used by patients, which Medicare covers. During the study period, Medicare did not cover oral hormone therapy or prescription drugs commonly used to treat pain or infection. We have defined phase-specific cancer-related monthly costs as the incremental difference between monthly costs among PCa patients and a cohort of patients without cancer matched according to age. This is an indirect approach to estimating costs related to the treatment of a disease. However, in an administrative database it is difficult to identify all costs related to the treatment of a specific condition using procedure and diagnostic codes. This is particularly true if patients are using general, non-cancer medical care to a greater extent versus non-cancer patients. This type of medical care cannot be captured using administrative codes.
We did not have complete Medicare cost data from diagnosis until death for many of the patients in this study because of censoring. Patients were censored if they were alive as of the last day of Medicare follow-up. To quantify the impact of censored data on results, we estimated costs using only the survival information for patients diagnosed during 1991 as this patient subgroup had the greatest number of uncensored patients. Results from this analysis showed that stage IV still had the highest PCa-related costs ($35 405). However, in contrast with the full sample results, costs for stages I-III descended with increasing stage at diagnosis (PCa-related costs, stage I $29 841, stage II $24 353, stage III $21 582). This result was expected because stage III patients had lower PCa-related continuing care costs relative to stages I and II. With a longer average period of follow-up among PCa patients diagnosed in 1991, the impact of continuing care costs is greater versus subgroups with shorter follow-up periods.
In estimating total and PCa-related costs, we used monthly cost inputs that were based on a sample of cases excluding patients with costs in the 95-100 percentiles. Thus, our estimates of the long-term total and PCa-related burden would have been higher had we included these patients in our estimation of monthly costs. Rather than estimating terminal PCa-related costs with an incremental approach using non-cancer controls, we could have used the clinical data in SEER to determine whether patients died from cancer and then considered their total terminal phase costs as related to PCa. However, we believe our approach is more appropriate because had these patients not developed PCa, they likely would have died from conditions similar to the non-cancer cohort and accrued substantial terminal costs. Thus, we assumed all PCa costs were those that could potentially be eliminated through PCa prevention strategies. From a Medicare payer perspective these details are important because they illustrate that, with our overall conservative approach, there is still a large cost burden associated with PCa.
We can combine our per-patient estimates of PCa costs with incidence data from the American Cancer Society 16 to gain an initial impression of the aggregate PCa cost burden imposed on the US health-care system. Our analyses suggest that each PCa case has an average initial PCa-related treatment cost of $11 142 ($1857 average monthly cost for each of the first 6 months after diagnosis). Adjusting this cost estimate to 2009 US dollars and combining it with data from the American Cancer Society estimating that 192 280 new PCa cases were diagnosed during 2009 yield a high aggregate PCa health-care cost burden of upwards of 2.5 billion dollars annually for initial care alone. This estimate does not include treatment costs for patients diagnosed before 2009.
Owing to improvements in screening modalities, patients are being diagnosed with PCa at younger ages and/ or earlier stages. Pharmacologic therapies that prevent or delay the onset of PCa could become important strategies for containing costs and improving patient outcomes. Our analyses quantify the medical-care costs related to PCa during initial, continuing, and terminal phases of PCa care. Furthermore, our analyses include patients diagnosed at distant stages as well as those receiving expectant management. To appropriately assess the economic benefits of prevention strategies, it is important to consider costs across all stages and treatment strategies.
Conflict of interest
Funding for this study was provided by GlaxoSmithKline (GSK) to United BioSource Corporation. Dr Peter Albertsen is a paid consultant to GSK and Blue Cross Blue Shield. Dr Albertsen also participates in a research study sponsored by sanofi-aventis. Libby K Black is an employee of GSK. Dr Claus G Roehrborn is currently a paid consultant to GSK and has been an investigator for GSK. Michael E Stokes and Á gnes Benedict are full-time employees of United BioSource Corporation.
End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database. Portions of this research were presented at American Urological Association Annual Meeting, 17-22 May 2008, Orlando, FL. This study was funded by GlaxoSmithKline.
